Personal Home Page

http://dgsom.healthsciences.ucla.edu/institution/personnel?personnel_id=8022

Articles in Scholarly Journals [Incomplete List]

1. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis
   Arthritis & Rheumatism, vol. 59, no. 6, pp. 867–875, 2008
2. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study
   Arthritis & Rheumatism, vol. 58, no. 7, pp. 1921–1930, 2008
3. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease
   Arthritis & Rheumatism, vol. 58, no. 6, pp. 1810–1822, 2008
4. Prepared patients: Internet information seeking by new rheumatology patients
   Arthritis & Rheumatism, vol. 59, no. 4, pp. 575–582, 2008
5. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
   Arthritis & Rheumatism, vol. 59, no. 5, pp. 699–705, 2008
6. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
   Arthritis & Rheumatism, vol. 59, no. 6, pp. 762–784, 2008
7. Serum Immunoglobulins and Risk of Infection: How Low Can You Go?
   Seminars in Arthritis and Rheumatism, 2008
8. Autoinflammatory diseases: an update of clinical and genetic aspects
   Rheumatology, vol. 47, no. 7, pp. 946–951, 2008
9. Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?
   PLoS ONE, vol. 3, no. 1, p. e1452, 2008
10. Treatment of the elderly rheumatoid arthritis patient
    Future Rheumatology, vol. 3, no. 3, pp. 235–238, 2008
11. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout
    Annals of the Rheumatic Diseases, vol. 67, no. 6, pp. 888–891, 2008
12. Assessing disease progression using a composite endpoint
    Statistical Methods in Medical Research, vol. 16, no. 1, pp. 31–49, 2007
13. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis
    Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 966–969, 2007
14. OPPOSITE attracts? Rationalizing therapy in rheumatology
    Future Rheumatology, vol. 2, no. 4, pp. 351–352, 2007
15. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
    Blood, vol. 110, no. 4, pp. 1388–1396, 2007
16. Clinical trials in systemic sclerosis: lessons learned and outcomes
    Arthritis Research & Therapy, vol. 9, no. Suppl 2, p. S7, 2007
17. Measuring Outcomes in PAH: The Gap between the Measures That Are Used and Their Validity
    Annals of the New York Academy of Sciences, vol. 1107, no. 1, pp. 410–416, 2007
18. High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease
    Chest, vol. 134, no. 2, pp. 358–367, 2007
19. Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort
    Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1633–1640, 2007
20. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?
    Rheumatology, vol. 46, no. 6, pp. 911–919, 2007
21. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
    Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 893–899, 2007
22. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
    Annals of the Rheumatic Diseases, vol. 66, no. Supplement 3, pp. iii2–iii22, 2007
23. Adult stem cell treatment of scleroderma
    Current Opinion in Rheumatology, vol. 19, no. 6, pp. 604–610, 2007
24. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
    Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1641–1647, 2007
25. Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    Annals of the Rheumatic Diseases, vol. 67, no. 5, pp. 703–709, 2007
26. Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel
    Rheumatology, vol. 47, no. 2, pp. 194–199, 2007
27. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
    American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 10, pp. 1026–1034, 2007
28. Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease
    American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 91–98, 2007
29. Pulmonary Complications of Connective Tissue Disease
    Seminars in Respiratory and Critical Care Medicine, vol. 28, no. 4, pp. 367–368, 2007
30. Health values of patients with systemic sclerosis
    Arthritis & Rheumatism, vol. 57, no. 1, pp. 86–93, 2007
31. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort
    Arthritis & Rheumatism, vol. 57, no. 3, pp. 440–447, 2007
32. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument
    Arthritis & Rheumatism, vol. 57, no. 7, pp. 1280–1286, 2007
33. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis
    Arthritis & Rheumatism, vol. 56, no. 12, pp. 3896–3908, 2007
34. Disease-Modifying Antirheumatic Drug Use in the Elderly Rheumatoid Arthritis Patient
    Rheumatic Disease Clinics of North America, vol. 33, no. 1, pp. 197–217, 2007
35. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis
    Quality of Life Research, vol. 16, no. 6, pp. 1083–1092, 2007
36. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study
    Arthritis & Rheumatism, vol. 56, no. 5, pp. 1676–1684, 2007
37. Gout and the risk of acute myocardial infarction
    Arthritis & Rheumatism, vol. 54, no. 8, pp. 2688–2696, 2006
38. Reply
    Arthritis & Rheumatism, vol. 54, no. 5, pp. 1709–1710, 2006
39. Allogeneic marrow transplantation in patients with severe systemic sclerosis: Resolution of dermal fibrosis
    Arthritis & Rheumatism, vol. 54, no. 6, pp. 1982–1986, 2006
40. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis
    Arthritis & Rheumatism, vol. 54, no. 2, pp. 607–612, 2006
41. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients
    Quality of Life Research, vol. 15, no. 8, pp. 1383–1394, 2006
42. Cyclooxygenase 2 controversy: Thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiology
    Arthritis & Rheumatism, vol. 55, no. 5, pp. 683–686, 2006
43. Recombinant human anti–transforming growth factor ß1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
    Arthritis & Rheumatism, vol. 56, no. 1, pp. 323–333, 2006
44. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus
    Arthritis & Rheumatism, vol. 54, no. 9, pp. 2951–2962, 2006
45. Target Populations in Allogeneic Hematopoietic Cell Transplantation for Autoimmune Diseases— A Workshop Accompanying: Cellular Therapy for Treatment of Autoimmune Diseases, Basic Science and Clinical Studies, Including New Developments in Hematopoietic and Mesenchymal Stem Cell Therapy1
    Biology of Blood and Marrow Transplantation, vol. 12, no. 6, pp. 688–690, 2006
46. Systemic sclerosis: hypothesis-driven treatment strategies
    The Lancet, vol. 367, no. 9523, pp. 1683–1691, 2006
47. Cyclophosphamide versus Placebo in Scleroderma Lung Disease
    New England Journal of Medicine, vol. 354, no. 25, pp. 2655–2666, 2006
48. Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection
    Seminars in Arthritis and Rheumatism, vol. 36, no. 3, pp. 159–167, 2006
49. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis
    Rheumatology, vol. 45, no. 12, pp. 1455–1457, 2006
50. A 1-year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus
    APLAR Journal of Rheumatology, vol. 9, no. 4, pp. 392–396, 2006
51. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
    Annals of the Rheumatic Diseases, vol. 65, no. 6, pp. 753–759, 2006
52. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year
    Annals of the Rheumatic Diseases, vol. 65, no. 8, pp. 1038–1043, 2006
53. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
    Annals of the Rheumatic Diseases, vol. 65, no. 10, pp. 1325–1329, 2006
54. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
    Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 169–173, 2006
55. Problems encountered during anti-tumour necrosis factor therapy
    Best Practice & Research Clinical Rheumatology, vol. 20, no. 4, pp. 757–790, 2006
56. Systemic and localized scleroderma
    Clinics in Dermatology, vol. 24, no. 5, pp. 374–392, 2006
57. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis
    New England Journal of Medicine, vol. 354, no. 8, pp. 795–808, 2006
58. Can Drug Effects Help Elucidate the Pathogenesis of SLE?
    Current Rheumatology Reviews, vol. 2, no. 3, pp. 233–244, 2006
59. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006
    Annals of the Rheumatic Diseases, vol. 65, no. suppl_3, pp. iii2–iii15, 2006
60. Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis
    Clinical Immunology, vol. 121, no. 1, pp. 118–119, 2006
61. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study
    Annals of the Rheumatic Diseases, vol. 64, no. 8, pp. 1180–1185, 2005
62. Meloxicam in rheumatoid arthritis
    Expert Opinion on Drug Metabolism Toxicology, vol. 1, no. 4, pp. 739–751, 2005
63. Updated consensus statement on biological agents, specifically tumour necrosis factor   (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
    Annals of the Rheumatic Diseases, vol. 64, no. suppl_4, pp. iv2–iv14, 2005
64. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
    Annals of the Rheumatic Diseases, vol. 64, no. 1, pp. 64–69, 2005
65. COX-2 controversy: where are we and where do we go from here?
    Inflammopharmacology, vol. 13, no. 4, pp. 395–402, 2005
66. Tacrolimus in Patients with Rheumatoid Arthritis
    Drugs, vol. 65, no. 7, pp. 1002–1003, 2005
67. Male microchimerism in women with systemic sclerosis and healthy women who have never given birth to a son
    Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 845–848, 2005
68. Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005
    Biology of Blood and Marrow Transplantation, vol. 11, no. 11, pp. 862–870, 2005
69. Ruminating on rheumatoid arthritis and transplantation
    Clinical Immunology, vol. 115, no. 2, pp. 129–130, 2005
70. Hemopoietic stem cell transplantation in rheumatic diseases—an update
    Autoimmunity Reviews, vol. 4, no. 7, pp. 442–449, 2005
71. HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women
    Rheumatology, vol. 44, no. 3, pp. 318–322, 2005
72. Mixed Connective Tissue Disease
    Rheumatic Disease Clinics of North America, vol. 31, no. 3, pp. xi–xii, 2005
73. Systemic Sclerosis Mortality in the United States: 1979–1998
    European Journal of Epidemiology, vol. 20, no. 10, pp. 855–861, 2005
74. Measuring the impact of managed care plans on the use of biologics
    Arthritis & Rheumatism, vol. 53, no. 3, pp. 318–319, 2005
75. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
    Arthritis & Rheumatism, vol. 52, no. 4, pp. 1020–1030, 2005
76. Disease-Modifying Antirheumatic Drug use in the Elderly Rheumatoid Arthritis Patient
    Clinics in Geriatric Medicine, vol. 21, no. 3, pp. 649–669, 2005
77. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study
    Arthritis & Rheumatism, vol. 52, no. 2, pp. 592–600, 2005
78. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    Arthritis & Rheumatism, vol. 52, no. 4, pp. 1227–1236, 2005
79. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes
    Arthritis & Rheumatism, vol. 52, no. 12, pp. 3873–3879, 2005
80. Reduction of the efficacy of methotrexate by the use of folic acid: Post hoc analysis from two randomized controlled studies
    Arthritis & Rheumatism, vol. 52, no. 10, pp. 3030–3038, 2005
81. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage
    Arthritis & Rheumatism, vol. 52, no. 8, pp. 2284–2292, 2005
82. Anti-tumor necrosis factor ? therapy and heart failure: What have we learned and where do we go from here?
    Arthritis & Rheumatism, vol. 50, no. 4, pp. 1040–1050, 2004
83. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
    Arthritis & Rheumatism, vol. 50, no. 4, pp. 1051–1065, 2004
84. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: Studies of healthy women and women with scleroderma
    Arthritis & Rheumatism, vol. 50, no. 3, pp. 906–914, 2004
85. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis
    Arthritis & Rheumatism, vol. 50, no. 6, pp. 1909–1917, 2004
86. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist
    Arthritis & Rheumatism, vol. 50, no. 12, pp. 3985–3993, 2004
87. Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: Comment on the article by Yocum et al
    Arthritis & Rheumatism, vol. 50, no. 9, pp. 3051–3051, 2004
88. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis
    Arthritis & Rheumatism, vol. 50, no. 9, pp. 2766–2774, 2004
89. Anakinra: Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis
    Clinical Therapeutics, vol. 26, no. 12, pp. 1960–1975, 2004
90. High-dose versus low-dose ?-penicillamine in early diffuse systemic sclerosis trial: lessons learned
    Seminars in Arthritis and Rheumatism, vol. 33, no. 4, pp. 249–263, 2004
91. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis
    Bone Marrow Transplantation, vol. 34, no. 10, Article ID 1704656, 4 pages, 2004
92. Infliximab in active early rheumatoid arthritis
    Annals of the Rheumatic Diseases, vol. 63, no. 2, pp. 149–155, 2004
93. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
    Clinical Immunology, vol. 113, no. 3, pp. 285–298, 2004
94. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience
    Rheumatology, vol. 43, no. 8, pp. 992–999, 2004
95. Contribution of common polymorphisms in reduced folate carrier and ??-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis
    Pharmacogenetics, vol. 14, no. 11, pp. 733–739, 2004
96. Relationships of Positive and Negative Affect to Coping and Functional Outcomes in Systemic Sclerosis
    Cognitive Therapy and Research, vol. 28, no. 5, pp. 593–610, 2004
97. Acquired resistance of human T cells to sulfasalazine
    Annals of the Rheumatic Diseases, vol. 63, no. 2, pp. 115–116, 2004
98. Safety of Tumour Necrosis Factor-?? Antagonists
    Drug Safety, vol. 27, no. 5, pp. 307–324, 2004
99. Updated consensus statement on biological agents, specifically tumour necrosis factor   (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
    Annals of the Rheumatic Diseases, vol. 63, no. suppl_2, pp. ii2–ii12, 2004
100. Current Opinion in Rheumatology, vol. 15, no. 3, pp. 197–204, 2003
101. Current Opinion in Rheumatology, vol. 15, no. 3, pp. 237–245, 2003
102. Comment on Furst??s Editorial: Postmarketing Surveys: Up Sides and Down Sides
     JCR: Journal of Clinical Rheumatology, vol. 9, no. 4, pp. 279–280, 2003
103. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
     Clinical Therapeutics, vol. 25, no. 6, pp. 1700–1721, 2003
104. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis
     Rheumatic Disease Clinics of North America, vol. 29, no. 2, pp. 409–426, 2003
105. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
     Biology of Blood and Marrow Transplantation, vol. 9, no. 9, pp. 583–591, 2003
106. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double-blind trial
     Arthritis & Rheumatism, vol. 48, no. 12, pp. 3328–3337, 2003
107. Adalimumab, a fully human anti–tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
     Arthritis & Rheumatism, vol. 48, no. 1, pp. 35–45, 2003
108. Glucocorticoids in the treatment of early and late RA
     Annals of the Rheumatic Diseases, vol. 62, no. 11, pp. 1033–1037, 2003
109. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis
     Arthritis & Rheumatism, vol. 46, no. 6, pp. 1460–1469, 2002
110. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study
     Arthritis & Rheumatism, vol. 46, no. 8, pp. 2020–2028, 2002
111. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon
     Arthritis & Rheumatism, vol. 46, no. 9, pp. 2410–2420, 2002
112. Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial
     Arthritis & Rheumatism, vol. 46, no. 11, pp. 2983–2989, 2002
113. Current Opinion in Rheumatology, vol. 14, no. 6, pp. 711–716, 2002
114. Current Opinion in Rheumatology, vol. 14, no. 3, pp. 220–224, 2002
115. Postmarketing Surveys
     JCR: Journal of Clinical Rheumatology, vol. 8, no. 6, pp. 295–296, 2002
116. Guidelines for the treatment of osteoarthritis
     Annals of the Rheumatic Diseases, vol. 61, no. 5, pp. 476–476, 2002
117. Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer
     Blood, vol. 100, no. 8, pp. 2845–2851, 2002
118. Recombinant Relaxin
     BioDrugs, vol. 15, no. 9, pp. 609–614, 2001
119. Immunoglobulin Binding Properties of the Prosorba Immunadsorption Column in Treatment of Rheumatoid Arthritis
     Therapeutic Apheresis and Dialysis, vol. 5, no. 2, pp. 84–91, 2001
120. D-penicillamine is not an effective treatment in systemic sclerosis
     Scandinavian Journal of Rheumatology, vol. 30, no. 4, pp. 189–191, 2001
121. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease
     Annals of the Rheumatic Diseases, vol. 60, no. 6, pp. 577–584, 2001
122. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial
     Rheumatology, vol. 40, no. 6, pp. 615–622, 2001
123. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial
     Arthritis & Rheumatism, vol. 44, no. 3, pp. 653–661, 2001
124. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma
     Arthritis & Rheumatism, vol. 44, no. 6, pp. 1351–1358, 2001
125. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate
     Arthritis & Rheumatism, vol. 44, no. 9, pp. 1984–1992, 2001
126. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis
     Arthritis & Rheumatism, vol. 44, no. 8, pp. 1848–1854, 2001
127. Combination therapy for autoimmune diseases: the rheumatoid arthritis model
     Springer Seminars in Immunopathology, vol. 23, no. 1-2, pp. 5–26, 2001
128. Aggressive strategies for treating aggressive rheumatoid arthritis: has the case been proven?
     The Lancet, vol. 356, no. 9225, pp. 183–184, 2000
129. Bone marrow transplantation in the treatment of systemic sclerosis
     Current Rheumatology Reports, vol. 2, no. 6, pp. 492–500, 2000
130. Oligo- and monoarticular inflammatory arthritis: A need and a hope
     Current Rheumatology Reports, vol. 2, no. 5, pp. 355–357, 2000
131. HLA–DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men
     Arthritis & Rheumatism, vol. 43, no. 9, pp. 2005–2010, 2000
132. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial
     Arthritis & Rheumatism, vol. 43, no. 11, pp. 2445–2454, 2000
133. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
     New England Journal of Medicine, vol. 343, no. 22, pp. 1594–1602, 2000
134. Immunoadsorption for the Treatment of Rheumatoid Arthritis: Final Results of a Randomized Trial
     Therapeutic Apheresis and Dialysis, vol. 4, no. 5, pp. 363–373, 2000
135. Rational therapy in the treatment of systemic sclerosis
     Current Opinion in Rheumatology, vol. 12, no. 6, pp. 540–544, 2000
136. Rofecoxib
     Expert Opinion on Pharmacotherapy, vol. 1, no. 5, pp. 1053–1066, 2000
137. Microchimerism of maternal origin persists into adult life
     Journal of Clinical Investigation, vol. 104, no. 1, pp. 41–47, 1999
138. Infliximab (chimeric anti-tumour necrosis factor ? monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
     The Lancet, vol. 354, no. 9194, pp. 1932–1939, 1999
139. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis
     Best Practice & Research Clinical Rheumatology, vol. 13, no. 4, pp. 689–700, 1999
140. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
     Arthritis & Rheumatism, vol. 42, no. 6, pp. 1194–1203, 1999
141. The prosorba column for treatment of refractory rheumatoid arthritis: A randomized, double-blind, sham-controlled trial
     Arthritis & Rheumatism, vol. 42, no. 10, pp. 2153–2159, 1999
142. Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis
     Arthritis & Rheumatism, vol. 42, no. 11, pp. 2372–2380, 1999
143. Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
     Archives of Internal Medicine, vol. 159, no. 21, pp. 2542–2550, 1999
144. Molecular model of the interaction between nimesulide and human cyclooxygenase-2
     Rheumatology, vol. 38, no. 90001, pp. 14–18, 1999
145. High-dose immunosuppressive therapy for rheumatoid arthritis: Some answers, more questions
     Arthritis & Rheumatism, vol. 42, no. 11, pp. 2269–2274, 1999
146. Reply
     Arthritis & Rheumatism, vol. 42, no. 7, pp. 1556–1556, 1999
147. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension
     Arthritis & Rheumatism, vol. 42, no. 2, pp. 357–365, 1999
148. Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial
     Arthritis & Rheumatism, vol. 41, no. 2, pp. 290–297, 1998
149. Clinical pharmacology of combination disease-controlling (DCART/DMARD) therapy in rheumatoid arthritis
     Zeitschrift f�r Rheumatologie, vol. 57, no. 1, pp. 20–24, 1998
150. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study
     Arthritis & Rheumatism, vol. 41, no. 4, pp. 670–677, 1998
151. BIOLOGIC AGENTS AND IMMUNOTHERAPY IN RHEUMATOID ARTHRITISProgress and Perspective
     Rheumatic Disease Clinics of North America, vol. 24, no. 3, pp. 537–565, 1998
152. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma
     The Lancet, vol. 351, no. 9102, pp. 559–562, 1998
153. Update on clinical trials in the rheumatic diseases
     Current Opinion in Rheumatology, vol. 10, no. 2, pp. 123–128, 1998